Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today [Yahoo! Finance]
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)
Last kiniksa pharmaceuticals international, plc - class a ordinary shares earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
It released its inaugural 2026 earnings report and, with key fundamentals that beat analyst estimates, grateful investors rushed into the stock, lifting it by almost 24% that day. Long-tail success Kiniksa, a commercial-stage biotech targeting afflictions with significant unmet need, published its first-quarter figures Tuesday morning. This revealed that revenue, comprised entirely of sales of multi-indication drug Arcalyst, rose to over $214 million from the year-ago tally of under $138 million. Will AI create the world's first trillionaire? Our team just released a report on a little-known company, called an "Indispensable Monopoly," providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Net income under generally accepted accounting principles (GAAP), meanwhile, more than doubled to $22.6 million from first quarter 2025's $8.5 million ($0.27 per share). Both headline figures convincingly beat the consensus analyst estimate
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Canaccord Genuity Group Inc. from $62.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Citigroup Inc. from $50.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wedbush from $58.00 to $59.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wells Fargo & Company from $53.00 to $57.00. They now have an "overweight" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ... [Yahoo! Finance]Yahoo! Finance
KNSA
Earnings
- 4/28/26 - Beat
KNSA
Sec Filings
- 4/29/26 - Form 4
- 4/28/26 - Form 144
- 4/28/26 - Form 10-Q
- KNSA's page on the SEC website